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Reactive, self-administered malaria 
treatment against asymptomatic malaria 
infection: results of a cluster randomized 
controlled trial in The Gambia
Joseph Okebe1,2, Edgard Dabira1, Fatou Jaiteh3,4, Nuredin Mohammed1, John Bradley5, Ndey-Fatou Drammeh1, 
Amadou Bah1, Yoriko Masunaga3,4, Jane Achan1,6, Joan Muela Ribera7, Shunmay Yeung8, Julie Balen9, 
Koen Peeters Grietens3 and Umberto D’Alessandro1* 
Abstract 
Background: Selectively targeting and treating malaria-infected individuals may further decrease parasite carriage in 
low-burden settings. Using a trans-disciplinary approach, a reactive treatment strategy to reduce Plasmodium falcipa-
rum prevalence in participating communities was co-developed and tested.
Methods: This is a 2-arm, open-label, cluster-randomized trial involving villages in Central Gambia during the 2017 
and 2018 malaria transmission season. Villages were randomized in a 1:1 ratio using a minimizing algorithm. In the 
intervention arm, trained village health workers delivered a full course of pre-packed dihydroartemisinin-piperaquine 
to all residents of compounds where clinical cases were reported while in the control arm, compound residents were 
screened for infection at the time of the index case reporting. All index cases were treated following national guide-
lines. The primary endpoint was malaria prevalence, determined by molecular methods, at the end of the intervention 
period.
Results: The trial was carried out in 50 villages: 34 in 2017 and 16 additional villages in 2018. At the end of the 2018 
transmission season, malaria prevalence was 0.8% (16/1924, range 0–4%) and 1.1% (20/1814, range 0–17%) in the 
intervention and control arms, respectively. The odds of malaria infection were 29% lower in the intervention than in 
the control arm after adjustment for age (OR 0.71, 95% CI 0.27–1.84, p = 0.48). Adherence to treatment was high, with 
98% (964/979) of those treated completing the 3-day treatment.
Over the course of the study, only 37 villages, 20 in the intervention and 17 in the control arm, reported at least one 
clinical case. The distribution of clinical cases by month in both transmission seasons was similar and the odds of 
new clinical malaria cases during the trial period did not vary between arms (OR 1.04, 95% CI 0.57–1.91, p = 0.893). All 
adverse events were classified as mild to moderate and resolved completely.
Conclusion: The systematic and timely administration of an anti-malarial treatment to residents of compounds 
with confirmed malaria cases did not significantly decrease malaria prevalence and incidence in communities 
where malaria prevalence was already low. Treatment coverage and adherence was very high. Results were strongly 
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Background
Where malaria transmission has reduced significantly, it 
has become extremely heterogeneous, with some loca-
tions having higher transmission intensity than sur-
rounding areas. Such locations are characterized by 
clusters of clinical cases, malaria-infected individuals 
with little or no symptoms and a variable health-seeking 
profile in the population [1]. While clinical cases point 
to on-going transmission, a significant proportion of 
malaria-infected individuals are asymptomatic, with low 
parasite densities over long periods, and able to infect 
mosquitoes [2]. Interventions that target these clusters 
with the aim of clearing the human reservoir of infection 
could accelerate the transition to elimination in areas on 
the cusp of reaching this milestone [3].
The concept of mass drug administration (MDA) 
and other versions of mass treatment campaigns have 
received renewed interest in the context of malaria elimi-
nation. These interventions involve repeatedly treating 
large swathes of the population with a full course of an 
anti-malarial, without ascertaining individual infection 
status. This assumes that, if implemented for a sufficiently 
long period, treatment would clear the human reservoir 
of infection and hence interrupt transmission [4].
MDAs are used against many infectious diseases [5] 
and were an essential strategy in some countries that 
achieved malaria elimination [6]. However, such levels of 
success have been difficult to replicate in recent clinical 
studies and treatment campaigns [7, 8]. The inability to 
reach and sustain the required levels of coverage is one 
of the main constraints to producing the anticipated 
impact on transmission. These treatment campaigns are 
expensive and difficult to implement efficiently. Cur-
rently, MDA is considered only for areas on the verge of 
interrupting transmission, with good access to treatment, 
effective vector control and surveillance systems, and 
minimal risk of re-introduction of infection [4].
There are other variants of mass drug treatment aimed 
at reducing infections in specific at-risk populations such 
as pregnant women and young children [9, 10]. These 
have been very successful and provide complementary 
evidence that targeted approaches can reduce the burden 
of disease in high-risk populations [11].
With improvements in malaria case management 
and surveillance, populations at high risk of infection 
and disease have been detected using data on passively 
reported malaria cases [12]. There is also evidence 
that clusters of asymptomatic parasite carriage and 
clinical cases can be spatially related; hence close con-
tacts of a malaria patient are more likely to be infected 
compared to a random sample of the population [13]. 
Based on this premise, treating these “household con-
tacts” for infection could further reduce transmission 
[14].
This “reactive” treatment has been implemented in 
some countries in sub-Saharan Africa [15, 16] and Asia 
[17]. The overall impact has been positive though, as 
with MDAs, it is influenced by several factors such as 
the local epidemiology [18], delivery strategy, response 
time [19], efficiency of local health systems [20] and 
underlying community structures [21]. There is clearly 
the need for evidence on reactive malaria treatment to 
support countries considering malaria elimination [22].
The Gambia has reported a significant reduction in 
the malaria burden over the last 15  years [23, 24] and 
is one of the few sub-Saharan African countries where 
interrupting transmission may be feasible [25]. To sup-
port this process, a trans-disciplinary approach was 
used to co-develop a reactive treatment strategy with 
participating communities, to deliver a full course of 
dihydroartemisinin-piperaquine (DP) to individuals liv-
ing in the same cluster of houses (compound contacts) 
of confirmed malaria patients attending the local health 
services. The efficacy of the intervention was tested in 
a cluster-randomized trial. The hypothesis was that 
timely reactive treatment of compound contacts of 
malaria cases, delivered through family members, can 
reduce both the incidence of clinical malaria during the 
transmission season and the prevalence of infection at 
the end of the transmission season.
Objective
The objective of this study was to determine whether 
prompt and systematic self-administered malaria treat-
ment by residents in a compound where a clinical 
malaria case occurred, reduces Plasmodium falciparum 
prevalence at the end of the transmission season.
influenced by the lower-than-expected malaria prevalence, and by no clinical cases in villages with asymptomatic 
malaria-infected individuals.
Trial registration:This study is registered with ClinicalTrials.gov, NCT02878200. Registered 25 August 2016.https:// clini 
caltr ials. gov/ ct2/ show/ NCT02 878200.
Keywords: Reactive treatment, Malaria prevalence, Asymptomatic infection, Village health worker
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Methods
Trial design
This was a two-arm, open-label, cluster-randomized 
controlled trial conducted in the Central Gambia region 
(Fig.  1). The unit of randomization was the village with 
trial procedures delivered to all residents in a compound 
based on the allocation of the village. The trial was con-
ducted between June and December, the period of 
malaria transmission in The Gambia, in the years 2016–
2018. The intervention was delivered between August 
and December each year, with post-intervention surveys 
conducted between November and December, in 2017 
and 2018. At the start of each study season, sensitization 
campaigns and census surveys were carried out to create 
a record of compound residents in the study area.
As part of the site preparation, messages about the 
trial objectives were curated by social scientists in the 
research team based on the views of the study population 
on malaria burden, access to care during illness, delivery 
of treatment and self-administration of medicines in the 
household [26]. These messages were refreshed to the 
communities during the sensitization campaigns.
Trial location and study participants
Malaria transmission in The Gambia is seasonal (July–
December) and varies in intensity across the country, 
with incidence of clinical malaria during the transmis-
sion season varying between 1.7 episodes/person-years 
in eastern Gambia to 0.2 and 0.1 episodes/person-years 
in central and western Gambia, respectively [27]. Malaria 
diagnosis and treatment (artemether-lumefantrine is 
the first-line treatment) services are available for free in 
all government clinics; in large communities (> 400 resi-
dents), trained resident village health workers (VHW) 
can perform diagnosis by malaria rapid diagnostic test 
(RDT) and treat positive cases for the residents of their 
community.
Villages on the North Bank East and Lower River health 
regions were purposely identified based on available data 
on malaria prevalence from field surveys [28] and clinical 
records of health facilities within the study area. Malaria 
prevalence by molecular methods in 2012 was 4.59% in 
the North Bank region and 9.36% in the Lower River 
region [28]. Each village is structured around family units 
or compounds. Each compound is defined by a location 
where one or several households made up of members 
of an extended patrilineal family reside. The compounds 
are usually headed by the oldest man in the family and 
his roles range from resource management to making 
health-related decisions. The living areas in the com-
pound are organized into living areas for the household 
head, married women who share them with their chil-
dren, and older boys.
Individual written informed consent for trial activities, 
including enumeration and cross-sectional surveys (all 
villages), was collected from residents of selected study 
villages. Additional consent was collected for procedures 
specific to the trial arm. In the intervention arm, consent 
to measure individual body weight and to deliver treat-
ment if a malaria case was identified in the compound 
was collected. In the control arm, consent was obtained 
to screen residents of compounds where a malaria case 
was reported. Consent procedures were updated for new 
members of the compounds identified during the pre-
season sensitization or when study procedures were to be 
conducted in the compound. The information provided 
was used to develop a logbook listing of residents by 
compound, which was used by the VHW to deliver treat-
ment or by the research team to screen compound mem-
bers. The details are presented in the trial protocol [29].
VHWs are an integral part of the local health system 
[30]. To embed the trial within the local health system, 
the VHWs were trained on how to deliver pre-packed 
doses of DP to compound residents of a malaria case, 
how to elicit and report on drug-related adverse events 
after treatment and to retrieve empty or unused treat-
ment from compound residents. The smaller study vil-
lages that did not have VHWs were invited to identify a 
Fig. 1 Map of the study area
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village resident who would report on confirmed cases and 
on adverse events to the study team. Such ‘village collab-
orator’ was trained to deliver questions on adherence to 
treatment and retrieve empty or unused treatment packs. 
Treatment for compounds without a resident VHW was 
delivered by a research nurse.
Randomization
Villages were randomized to one of the two arms using 
a computer-generated minimization algorithm by the 
trial statistician. Concealment of allocation was not fea-
sible as all participants and study field staff were aware 
of village allocations, nor blinding of the treatment was 
feasible. However, laboratory staff processing samples 
were blinded to the source of the samples as these were 
labelled with unique codes delinked from the study 
identifiers.
The intervention
The intervention comprised treating with a full treat-
ment of weight-calculated dose of DP all residents of a 
compound where a malaria case was reported. To ensure 
ease and prompt delivery, VHWs were given a start-
up pack that included a treatment box containing pre-
packed doses of DP, a logbook with residents listed by 
compound, and weight-derived, pictorial treatment chart 
developed during the trial preparation sessions with the 
community leaders (Fig.  2). The pre-packed doses were 
prepared based on the manufacturer’s weight recom-
mendation and labelled with stickers corresponding to 
the pictures on the logbook. The drugs were replenished 
by the research nurse after each compound had been 
treated.
Residents in all study villages were encouraged to visit 
their VHW when they were unwell for a malaria test. 
When an individual tested positive for malaria, they 
were treated with artemether-lumefantrine according 
to national guidelines. The VHW then visited the com-
pound of this index case and delivered to the compound 
head, with instructions on how and when it should be 
taken, sufficient DP doses to treat all residents. VHWs 
visited the compound 4  days later to retrieve unused 
medicines and empty medicine packs, and record any 
adverse events.
Fig. 2 Poster message on use of dihydroartemisinin-piperaquine handed to “treated” compounds
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A study nurse accompanied the VHW during their first 
visits to compounds to be treated. Subsequent visits were 
carried out by the VHW alone. In case of a new resident 
or person without a written informed consent, the VHW 
informed the supervising study nurse who visited the 
compound and obtained the informed consent before 
administering treatment.
Procedures in the control arm
In the control arm, VHWs treated index cases with 
artemether-lumefantrine and reported these events to 
the study nurse who visited the compound within 5 days 
to collect a finger-prick blood sample from all residents. 
These samples were transferred to the central laboratory 
where they were stored until molecular diagnosis for P. 
falciparum infection. Residents who were symptomatic 
at the time of the visit were offered an RDT and, if posi-
tive, treated with artemether-lumefantrine.
Sample processing
Plasmodium falciparum DNA was isolated from dried 
blood spots using an automated QIAcube HT extrac-
tor robot  (Qiagen®). Positive and negative controls were 
included during extraction to assess efficiency of DNA 
extraction and the risk of contamination, respectively. 
5  µL of extracted DNA was used in an ultrasensitive 
real-time PCR assay [31] with 3D7 standards of known 
parasite concentration serially diluted and used to gener-
ate standard curves and set limits of parasite DNA detec-
tion. Quantification cycle (Cq) values of test samples 
above the limit of detection scored as positive. Samples 
with borderline Cq values were scored independently by 
a second reader and, where results remained discrepant, 
DNA from the sample was re-extracted and the process 
repeated. All results were analysed using the BIO-RAD 
CFX96 Touch™ Real-Time PCR detection system.
Endpoints
The primary endpoint was P. falciparum prevalence, by 
molecular methods, in all age groups at the end of the 
intervention period. Following disruptions due to local 
political unrest in the country and a very short rainy sea-
son in 2017, the trial was extended for 1  year with the 
trial endpoint deferred to the end of the 2018 transmis-
sion season.
For the cross-sectional surveys, the sample size needed 
to show a 60% difference in prevalence between the 
arms was estimated assuming a 5% prevalence in the 
control arm, 80% power and 5% significance level. A 
random sample of all listed residents was drawn from 
each village, in proportion to the village size. Each vil-
lage was informed through the resident VHW about the 
survey and once specific dates were agreed, the VHW 
disseminated the information to the village. On the 
scheduled day, study teams with support from volun-
teers, approached the selected persons in the compounds 
and invited them to meet at a central location where 
blood sampling was done. Selected persons who were 
absent or refused to participate were not replaced on 
the list. A finger-prick blood sample was collected onto 
Whatman filter paper, air-dried, and transported to the 
laboratory for P. falciparum parasite detection using the 
same protocol described above [31].
The secondary endpoints included the incidence of 
clinical malaria cases (diagnosed by RDT) as detected 
through the health system, in both intervention and con-
trol clusters, and treatment coverage as determined by 
percentage of individuals living in the same compound 
having received and taken at least 80% of the prescribed 
dose. For this, a combination of the count of medicine 
packs and tablets returned and the VHW feedback where 
medicine packs were not accounted for was used.
Sample size consideration
It was assumed the intervention would decrease malaria 
prevalence by at least 60%, i.e., from 5 to 2% or less [28]. 
With 34 villages, 17 per arm, the trial would be able to 
detect such effect at 80% power, 5% significance level 
and 0.7 coefficient of variation. However, in November 
2017, malaria prevalence in the control arm was lower 
than expected (2.8%). After approval by the Steering Trial 
Committee and the funder, 16 additional villages in the 
South Bank of the river Gambia, 8 per arm were added to 
increase the power of the study.
Data management and statistical analysis
Information on treatment delivered, adherence and 
retrieval of blister packs and unused medicines were 
recorded on paper forms by the study nurse at sched-
uled visits to each VHW. The study nurses also collected 
information on persons screened for infection in control 
villages. These forms were submitted to the field station 
where they were checked for consistency by the study 
coordinator before double-entry by data clerks. Forms 
were entered onto the trial database on OpenClinica 
(OpenClinica, LLC). Laboratory results were directly 
exported onto a Microsoft Access database. Data from 
the field were linked with the laboratory results during 
analysis.
The data analysis followed an agreed statistical ana-
lytical plan based on the published protocol [29]. The 
prevalence of malaria infection was calculated as the pro-
portion of sampled population during the end-of-season 
surveys with a positive PCR result; the period prevalence 
of clinical episodes was defined as the number of posi-
tive malaria cases detected by RDT, in the entire study 
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population during the intervention period (August–
December). Both outcomes were compared between 
arms using a random effects logistic regression model to 
give an odds ratio of the effect of the intervention.
Changes to protocol
Two unexpected events during the trial informed addi-
tional data analyses and are presented as “unplanned 
analysis”. The extension of the trial for an additional year/
transmission season provided an opportunity to assess 
the effect of the intervention across two transmission 
seasons. Unexpectedly, many villages in both arms and in 
both years did not record any clinical case and thus, if in 
the intervention arms, did not receive any treatment. For 
this reason, the results are presented as per a pre-spec-
ified analysis plan and an unplanned analysis, restricted 
to villages where at least one clinical case was reported. 
Since this unplanned analysis included fewer clusters, the 
data over the two study years were combined to maintain 
statistical power. In the cross-sectional survey results, an 
unplanned subgroup analysis by age is reported.
Results
Sixty-five villages were purposely screened for eligibility: 
45 and 20 in the 2017 and 2018 malaria transmission sea-
sons, respectively. Of this, 50 were included in the trial; 
34 in the 2017 season and 16 additional villages in the 
2018 season. Reasons for exclusion are shown in the trial 
flow diagram (Fig. 3).
The study population comprised 18,975 residents in 
1319 compounds, with a median of 269 (range 34–2147) 
residents per village. The number of compounds were 
similar in both arms (Table  1). About half (51.7%, 
9816/18,975) of the population and 45.8% (604/1319) of 
compounds were in the 34 villages in the North Bank. 
About half (51.6%) of the population was female, with 
no significant difference in gender distribution between 
arms. In the population who knew their age (82.5%, 
15,657/18,975), the median age was 15.5 (range 0.1–87.9) 
years, with 12.7% (1982/15657) below 5 years. Thirty-six 
(72.0%) villages had a resident VHW, 19 of them in vil-
lages in the intervention arm.
Planned analysis
End‑of‑season malaria prevalence
In 2018, malaria prevalence at the end of the transmis-
sion season was 0.8% (16/1924, range 0–4%) and 1.1% 
(20/1814, range 0–17%) in the intervention and con-
trol arms, respectively (Table 2). After adjusting for age, 
prevalence was not significantly lower in the intervention 
compared to the control arm (OR 0.71, 95% CI 0.27–1.84, 
p = 0.48).
In 2017, malaria prevalence was 1.8% (23/1259) and 
2.4% (39/1638) in the intervention and control arms, 
respectively. The prevalence was not significantly lower 
in the intervention compared to the control arm after 
adjusting for age (0.54, 95% CI 0.21–1.37, p = 0.193, 
Table 3).
Period prevalence of clinical malaria cases
The peak in clinical cases occurred between September 
and November (Fig. 4). During the 2018 season, 71 cases 
were reported in 11 of the 25 intervention villages: eight 
villages in the South Bank and three villages in the North 
Bank (Table  2). Only six (8.5%, 6/71) of the reported 
cases were from the North Bank, each of them from dif-
ferent compounds. There were 85 clinical cases reported 
in 14 (14/25, 56.0%) control villages, 13 (15.3% 13/85) of 
the cases were from the North Bank. There was no dif-
ference in period prevalence of clinical malaria between 
the intervention (0.8%, 71/8645) and the control (0.8%, 
85/10330) arm (OR 1.04, 95% CI 0.57–1.91).
During the 2017 season, there were 12 malaria cases 
reported in five (29.4%) of the 17 intervention villages, 
with 239 registered residents in these compounds, with 
the median compound size of 17 (range 5–37) residents. 
In the control arm, 18 clinical cases were reported from 
seven villages.
Treatment coverage and adherence (intervention arm only)
Compound visits were carried out for all recorded cases. 
In 2018, there were 1014 residents listed in the com-
pounds of index cases, with the median of 12 (range 
3–60) residents per compound. Most listed residents 
(96.6%, 979/1014) were present at the time of the visit 
and received treatment. Adherence to treatment was 
high as 98.5% (964/979) of those treated completed the 
full 3-day treatment. In 2017, most of the compound resi-
dents (95.0%, 227/239) were treated and, among these, 
96.5% (219/227) completed the three doses of treatment.
Parasite infection among screened compound residents 
(control arm only)
The period prevalence of infection in screened com-
pounds, i.e., at the time a case of clinical malaria was 
diagnosed, was 5.1% (67/1316); the population preva-
lence in the control arm, measured at the end of the 
transmission season, was 1.1% (20/1814). When compar-
ing period prevalence with the population prevalence at 
the end of the transmission season, malaria prevalence 
was on average 2.2% (95% CI 0.3%–4.2%, p = 0.027) 
higher in compounds with a clinical case.
In 2017, the prevalence among screened compound 
residents was 3.3% (33/1014) while population preva-
lence at the end of the transmission season was 2.9% 
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(49/1679). When comparing these two estimates, malaria 
prevalence was on average 0.6% (95% CI −7.5%, 8.8%, 
p = 0.853) higher in compounds with a clinical case.
Unplanned analyses
Malaria prevalence in 2017 and 2018 seasons
When combining 2017 and 2018, the average malaria 
prevalence was 1.2% (39/3183, range 0–10.5%) in the 
intervention arm and 1.7% (59/3452, range 0–13.3%) in 
the control arm (OR 0.65, 95% CI 0.37–1.15, p = 0.138).
Malaria prevalence in villages reporting at least one malaria 
case
Over the course of the study, 37 villages, 20 in the inter-
vention and 17 in the control arm, reported at least one 
clinical case (Table 4). When combining both years and 
adjusting for age, prevalence was about 50% lower in 
the intervention than in the control arm (OR 0.51, 95% 
CI 0.3–0.86, p = 0.013). The difference in malaria preva-
lence between study arms was particularly marked in 
children under 5 years of age (OR 0.12, 95% CI 0.2–0.58, 
p = 0.009).
Fig. 3 Consort flow diagram for the trial
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Adverse events reported during drug treatment
In 2018, 32 (84.2%) of the 38 adverse events were con-
sidered as mild and 6 as moderate. In 2017, 37 adverse 
events were recorded, all were categorized as mild. 
No severe adverse event was reported in both years. 
The moderate adverse events were headache (reported 
twice), diarrhoea, abdominal pain, joint pain, and cough 
(Table 5).
Discussion
Systematic and timely administration of an antimalarial 
treatment to all residents of compounds with clinical 
malaria patients may reduce malaria prevalence. How-
ever, prevalence at the end of the 2018 transmission sea-
son was not significantly different between study arms, 
partly due to the lower-than-expected prevalence and 
to the presence of asymptomatic malaria-infected indi-
viduals in villages without a single case of clinical malaria 
throughout the whole transmission season. Indeed, the 
recorded prevalence of 1.1% in the control arm at the 
end of the study was greatly different from the initial 
assumption of 5%. Almost half of the intervention vil-
lages, mostly in the North Bank, did not report any clini-
cal malaria case and thus did not receive any treatment. 
Nevertheless, clustering of asymptomatic infections 
around clinical cases seems to occur; in control villages, 
malaria prevalence in compounds with clinical cases was 
higher than the population-level prevalence recorded at 
the end of the transmission season survey. This suggests 
some asymptomatic malaria-infected individuals do not 
easily transmit their infection to the vector, particularly 
when parasite/gametocyte densities are low [32]. Most 
infections detected at the end of the transmission sea-
son surveys were of low density and not associated with 
symptoms. The low malaria prevalence in these villages, 
often below 5%, and the low probability of transmission 
from the few infected individuals to the vector would 
explain the lower-than-expected effect of the interven-
tion [32]. Nevertheless, malaria prevalence in children 
under 5 years of age was substantially lower in the inter-
vention than in the control villages, and consistently so 
in both study years although it reached statistical signifi-
cance only in 2018 (Table 2), suggesting the intervention 
was efficacious in this age group.
Trials of reactive treatment in other low transmission 
settings have also showed similar effectiveness without 
reaching statistical significance [33], highlighting the 
influence of background fluctuations in malaria transmis-
sion on the impact of interventions designed to interrupt 
transmission.
The malaria burden in the study area was low [34, 35] 
and transmission may have been extremely localized, 
with clinical episodes representing spikes of transmission 
Table 1 Baseline characteristics of study area and population
* Based on 82.6% (15,681/18,975) of the population that provided their age
Total Intervention Control
Number of villages 50 25 (50.0%) 25 (25.0%)
Villages on the North 
bank
34 17 (68.0%) 17 (68.0%)
Number of compounds 1319 670 (50.8%) 649 (49.2%)
Population 18,975 8645 (45.6%) 10,330 (54.4%)
Female 9790 4486 (45.8%) 5304 (54.2%)
Villages with resident vil-
lage health worker
36 19 (52.8%) 17 (47.2%)











Population by age group*
 Under 5 1957 852 (43.5%) 1105 (56.5%)
 5–14 5665 2271 (40.1%) 3394 (59.9%)
 15–30 3703 1468 (39.6%) 2235 (60.4%)
 Over 30 4356 1734 (39.8%) 2622 (60.2%)
Table 2 The prevalence of parasite infection and period 
prevalence of clinical cases for all study villages in 2018 (n = 50)
a Random effects logistic regression models are not valid with a small number of 
clusters per arm so a t test on cluster level summaries was used; in these cases, a 
risk ratio is presented instead of an odds ratio
b Adjusted for age




 All  clustersb 0.8% (16/1924) 1.1% (20/1814) 0.71 (0.27, 1.84) 
p = 0.48
 North bank 0.3% (4/1246) 0.1% (1/1134) 3.58 (0.4, 32.1) 
p = 0.255
South  banka 1.8% (12/665) 2.8% (19/669) 0.61 (0.29, 1.26) 
p = 0.182
By age
 Under 5 years 0.4% (1/237) 3.5 (7/199) 0.11 (0.01, 0.94), 
p = 0.043
 5–14 years 0.5% (4/783) 0.7% (5/769) 0.84 (0.22, 3.17), 
p = 0.8
15–30 years 1.9% (6/323) 0.7% (2/279) 2.76 (0.55, 13.9), 
p = 0.219
Above 30 years 0.9% (5/567) 1.1% (6/555) 0.88 (0.26, 2.91), 
p = 0.83
Period prevalence of clinical malaria
 All clusters 0.8% (71/8645) 0.8% (85/10330) 1.04 (0.57, 1.91) 
p = 0.893
 North bank 0.2% (6/3752) 0.2% (13/6064) 0.77 (0.23, 2.54) 
p = 0.664
 South bank 1.3% (65/4893) 1.7% (72/4266) 0.81 (0.34, 1.92) 
p = 0.613
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within compounds but not sufficiently intense to spread 
to the whole village. The only vector control measures 
implemented in the region are insecticide-treated nets 
(ITN), whose last distribution was done during the study, 
in 2017. In the study area, ITN coverage rates was high, 
above 70% [27], making this area suitable for the evalu-
ation of interventions such as reactive treatment target-
ing residual transmission. Reactive treatment relies on 
the identification of clinical cases to target treatment to 
individuals likely to be infected. However, there may be 
clusters of malaria-infected individuals without necessar-
ily the occurrence of clinical cases [33], thus diluting the 
effect of the intervention.
This approach for delivering the intervention consid-
ered social structures in the community; the compound 
as a microcosm of the community, the VHW’s role as 
the health expert and local social groups, providing a 
link between research and the formal health system. By 
involving these stakeholders (including VHWs, village 
development groups, traditional birth attendants) in the 
development and the adaptation of the intervention, e.g., 
malaria case reporting, drug delivery and administra-
tion, high treatment coverage and adherence in both sea-
sons was achieved [26], 19,21. In addition, a protocol of 
regular contact between research nurses and VHWs was 
rigorously applied to review malaria reports and discuss 
Table 3 The prevalence of parasite infection and period prevalence of clinical cases for all study villages in 2017 (n = 34)
a Random effects logistic regression models are not valid with a small number of clusters per arm so a t test on cluster level summaries was used; in these cases, a risk 
ratio is presented instead of an odds ratio
Outcome Intervention Control Odds ratio (95% 
confidence interval)
Infection  prevalencea 1.8% (23/1259) 2.4% (39/1638) 0.54 (0.21, 1.37), p = 0.193
By age
 Under 5 years 1.1% (2/191) 3.7% (10/2720) 024 (0.05, 1.31), p = 0.101
 5–14 years 1.7% (9/538) 1.6% (11/698) 0.91 (0.29, 2.81), p = 0.865
 15–30 years 3.0% (6/201) 3.6% (9/252) 0.64 (0.18, 2.31), p = 0.498
 Above 30 years 1.8% (6/333) 2.1% (0/425) 0.81 (0.23, 2.8), p = 0.734
Period prevalence of clinical malaria 0.3% (12/3752) 0.3% (18/6064) 0.95 (0.30–2.97), p = 0.930
Fig. 4 Distribution of clinical cases in the transmission season (both 
seasons combined)
Table 4 End-of-season prevalence of infection in study villages where at least one clinical case was reported
Outcome Intervention Control Odds ratio (95% 
confidence interval)
Infection prevalence
 2018 (all clusters) 0.9% (14/1629) 1.4% (20/1399) 0.51 (0.18, 1.41), p = 0.194
 North bank 0.2% (2/952) 0.1% (1/726) 1.64 (0.14, 18.1), p = 0.688
 South bank 1.8% (12/677) 2.8% (19/673) 0.61 (0.29, 1.26), p = 0.182
2017 1.2% (12/975) 2.4% (32/1322) 0.51 (0.25, 1.05) p = 0.07
 Combined both seasons 1.0% (26/2604) 1.9% (52/2721) 0.51 (0.3, 0.86) p = 0.013
By age
 Under 5 years 0.5% (2/368) 3.9% (15/382) 0.12 (0.02, 0.58), p = 0.009
 5–14 years 0.8% (8/1072) 1.2% (14/1140) 0.59 (0.21, 1.64), p = 0.311
 15–30 years 1.9% (8/428) 2.5% (10/403) 0.71 (0.24, 2.1), p = 0.532
 Above 30 years 1.1% (8/736) 1.6% (13/795) 0.61 (0.22, 1.75), p = 0.361
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trial progress during monthly meetings. Together with 
the community engagement, it is unlikely clinical cases 
were missed.
Community members were aware of the direct and 
indirect impact of malaria. They considered that the 
treatment given to compound residents was beneficial 
as it protected vulnerable individuals within the fam-
ily while resulting in economic benefits from time spent 
away from work during the farming season if sick, and 
savings on cost of medicines [26]. This underscores the 
importance of trans-disciplinary studies aimed at align-
ing community and programme expectations when plan-
ning mass treatment interventions [30].
While not recommended, an unplanned analysis was 
carried out to better understand the effect of the inter-
vention and the influencing factors. Including in the 
analysis only villages with at least one clinical malaria 
case, both for the intervention and control arm, is justi-
fied by the fact that villages without any clinical case did 
not receive any intervention. With hindsight, a different 
approach, although logistically challenging, could have 
been to set up a malaria surveillance system over a larger 
area and recruit throughout the transmission season only 
villages with clinical cases as soon as these were reported.
When including only villages with at least one clinical 
malaria case and after adjusting for age, prevalence in the 
intervention arm was about 50% lower than in the control 
arm, both in 2017 and 2018, although the trial remains 
underpowered for the initial estimated effect. These 
results are consistent with the assumption of localized 
transmission and infection progressing to clinical disease 
in non-immune members of the population. Indeed, the 
lower risk of infection in children under 5 years suggests 
that these were recent infections successfully treated by 
the intervention. This range of effect is reported from 
similar studies [33, 36]. However, none of these stud-
ies were able to show statistically significant differences 
following the intervention. A pooled analysis of these 
studies would be useful to better understand the impact 
and role of reactive interventions in interrupting malaria 
transmission. It would also feed into modelling studies 
to determine settings where the impact is maximized in 
reducing or interrupting transmission. Studies to test the 
effectiveness of long-term markers of transmission [37, 
38] and monitoring variability in the risk of transmission 
in such low transmission settings [39, 40] are needed to 
assess the long-term impact of reactive treatment on par-
asite carriage and malaria transmission.
Mass treatment campaigns are characterized by syn-
chronous treatment of defined populations within a fixed 
period and effectiveness is linked to levels of coverage 
and adherence to treatment. Studies on reactive treat-
ment have applied a “campaign approach” and report 
on operational challenges with hard-to-reach places, 
response times and ensuring coverage for at risk persons 
[16, 19, 41]. By integrating health messages and using 
resources close to the “target treatment area”, it was pos-
sible to deliver treatment timely, with consistent high 
coverage and adherence rates. This highlights the value 
of investing in methods for delivering interventions, 
acknowledging that “one-size-fits-all” would not be able 
to achieve optimal coverage. In addition, scalability of 
the delivery approach should consider how to adapt the 
research-specific procedures to context. These include 
using existing enumeration data that is updated when a 
compound needs to be treated and using age or height 
derived estimates for dosing.
A key challenge to the process was ensuring the VHW 
had sufficient quantities of RDTs and artemether-lume-
fantrine throughout the transmission season. Due to 
reporting requirements for these commodities, illiter-
ate VHWs could not receive RDTs even if they had been 
trained for their use. This was addressed by engaging 
with the regional health team and exploring ways to bet-
ter support VHWs. These included allowing a literate 
member of the VHW’s family to complete the report and 
requisition forms for RDT and artemisinin-based combi-
nation therapy (ACT), and deliver supplies when visiting 
the VHW for supervision.
Conclusion
Reactive, community-based targeted interventions deliv-
ered through local health structures attended by clini-
cal cases may reduce malaria prevalence at the end of 
the transmission season. However, the trial was not suf-
ficiently powered to show a significant effect due to a 
lower-than-expected malaria prevalence in the study 
area and the presence of asymptomatic malaria-infected 
Table 5 Adverse events, by year, in participants who received 
dihydroartemisinin-piperaquine
Adverse event 2017 2018 Total n (%)
Vomiting 8 3 11 (14.7)
Loose stools 4 6 10 (13.3)
Diarrhoea 0 7 7 (9.3)
Dizziness 3 4 7 (9.3)
Nausea 6 1 7 (9.3)
Body aches 5 1 6 (8.0)
Abdominal pain 1 4 5 (6.7)
Headache 2 3 5 (6.7)
Tiredness 2 3 5 (6.7)
Weakness 4 1 5 (6.7)
Others 2 5 7 (9.0)
Total 37 38 75 (100.0)
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individuals in villages without any clinical malaria case. 
Both treatment coverage and adherence levels were 
high, with DP well tolerated and without major safety 
concerns.
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